See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
Artificial Intelligence
European Union
Social Media
Stock Markets
MLB
Natural Disasters
Republican Party
Bitcoin
US Politics
Taxes
Cricket
Published • loading... • Updated

Pfizer and Astellas’ Xtandi improves OS as combination therapy

Summary by Clinical Trials Arena
Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.The post Pfizer and Astellas’ Xtandi improves OS as combination therapy appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Clinical Trials ArenaClinical Trials Arena

Pfizer and Astellas’ Xtandi improves OS as combination therapy

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with nmHSPC, but only as a combination therapy.The post Pfizer and Astellas’ Xtandi improves OS as combination therapy appeared first on Clinical Trials Arena.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Friday, July 11, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal